3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
127
Carboplatin
125
Pemetrexed
105
Cisplatin
79
Paclitaxel
58
osimertinib
55
Nivolumab
52
Docetaxel
52
durvalumab
48
Specimen Handling
40
Magnetic Resonance Spectroscopy
36
Gemcitabine
35
Radiosurgery
29
atezolizumab
27
Cetuximab
26
130-nm albumin-bound paclitaxel
26
Radiotherapy
22
Ipilimumab
21
Drug Therapy
21
cemiplimab
20
Bevacizumab
20
amivantamab
18
Taxes
16
Ramucirumab
13
tislelizumab
12
alectinib
12
Biopsy
12
lazertinib
11
Radiation
11
Oxaliplatin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
2,2'-dithiodiethanesulfonic acid
×
90 days
×
Clear all
NCT05456256
2026-05-04
HARMONIC
Lantern Pharma Inc.
Phase 2
Recruiting
90 enrolled